Participating Faculty: Clinical Trial Designs in PAH: Shifting From Functional Measurements to Long-term Clinical Outcomes

Published Online: March 23, 2014
Sean M. Studer, MD, MSc, and Robert J. Gilkin, Jr, RPh, MBA
This supplement to The American Journal of Managed Care provides an overview of the economic burden of pulmonary arterial hypertension (PAH) and the current state of its management. Also discussed is the evolution of clinical trial design in PAH that includes a move away from the use of 6-minute walk distance as a primary end point and toward morbidity and mortality composite end points that better reflect disease progression.
This supplement was sponsored by Actelion Pharmaceuticals US, Inc.


Sean M. Studer, MD, MSc

Chief of Medicine

Associate Professor of Clinical Medicine

New York University

New York, New York

Robert J. Gilkin, Jr, RPh, MBA

Vice President

Gemini Healthcare, LLC

Westbrook, Connecticut

Faculty Disclosures

These faculty report relationships with the following organizations:

Sean M. Studer, MD, MSc

Consultant or paid advisory board/lecture fees:

Actelion Pharmaceuticals, Bayer, Gilead, and United Therapeutics Corporation.

Robert J. Gilkin, Jr, RPh, MBA


Actelion Pharmaceuticals and Pfizer.

Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.

Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, the editorial staff, or any member of the editorial advisory board. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, is not responsible for accuracy of dosages given in articles printed herein. The appearance of advertisements in this publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.

Recommended Articles
The announced price for alirocumab, the first PCSK9 inhibitor approved for use in the US, was the top story in managed care this week. Also, HHS announced $100 million available to combat substance abuse, and Medicare and Medicaid turn 50 years old.
Congressman Frank Pallone, Jr (D-NJ), explains the purpose of the National Institutes of Health Innovation Fund, which allows the organization to find cures for diseases that don’t have 1 yet.
Proposed mergers of Aetna and Humana, and Anthem and Cigna, raise questions of whether consumers will continue to see competition in health insurance markets.
Fifty years ago today, President Lyndon B. Johnson signed the law that created Medicare and Medicaid, setting in motion not only the greatest change in healthcare in the nation's history at that point, but also a lasting change for society.
Officials say the number of enrollees and their relative good health made it possible to negotiate lower rate increases. However, premium increases are higher in Northern California, where there is less competition.